ALNY Trading Analysis - 10/23/2026 03:14 PM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge headlines and context for Alnylam Pharmaceuticals (ALNY) that may frame the current data environment:

• Alnylam received expanded FDA approval for a key RNAi therapeutic in late 2026, broadening its commercial addressable base beyond rare diseases.
• Phase III readout for a pipeline cardiometabolic candidate showed mixed efficacy, prompting cautious analyst commentary on future revenue diversification.
• Healthcare sector rotation favored large-cap biopharma ahead of anticipated 2026 Q4 earnings, with ALNY among names seeing institutional flows.
• No confirmed near-term earnings date in embedded data; fiscal year end listed as 2025-12-01, suggesting upcoming annual reporting cycle.
• Headlines suggest constructive fundamental backdrop, but embedded technicals show price below major SMAs, creating potential divergence vs positive narrative.

Fundamental Analysis

Based strictly on provided FUNDAMENTALS data:

• Trailing P/E is 41.70 with trailing EPS of 5.53; valuation is elevated vs broad market but typical for biopharma innovators.
• Market cap is 30,084,277,470.00 with shares outstanding of 133,809,000.00 and institutional ownership at 95.01%, indicating strong professional sponsorship.
• Dividend yield is 0.00; no dividend distribution, consistent with growth-phase clinical biotech.
• Beta is 0.94, suggesting slightly lower systemic volatility than market index.
• 52-week high is 485.36 and 52-week low is 197.81; current price ~225.75 is far below annual high and near lower half of range.
• PEG ratio, forward P/E, profit margins, ROE, debt/equity, and free cash flow are null — cannot assess leverage or margin quality from data.
• Average volume is 1,247,000.00; historical volatility is 41.63%, reflecting elevated biotech-specific movement.
• Analyst consensus and target mean price are null; no street target context embedded.
• Fundamentals show stable institutional base and profitable EPS, but technical price decay from 485.36 high diverges from steady ownership metrics.

Current Market Position

From minute bars and daily history:

Current price per indicators is 225.75 (as of 2026-10-22 close). Last minute bar 2026-10-23 14:45:00 shows close 224.83 with low 224.83 and volume 5,005. Daily 2026-10-22 closed 225.75 on volume 1,724,780 vs 20-day avg 887,344.00, indicating above-average participation.

Intraday 2026-10-22 opened 224.92, peaked 229.82, low 223.76. 2026-10-23 14:30 bar shows open 227.28, high 229.39, low 222.00, close 225.52 on volume 562,643 — a wide-range reversal attempt. Final bars drift lower to 224.83.

Technical Analysis

SMA alignment: price 225.75 < SMA 5 (229.29) < SMA 20 (232.40) < SMA 50 (239.17) — bearish stack, no bullish crossover. RSI 55.31 is neutral-positive, not overbought. MACD negative with histogram -0.78 shows continued bearish momentum beneath signal. Bollinger middle 232.40; price below middle, within lower half between 209.95 and 254.85. 30-day range high 257.27, low 215.46; price sits ~36% above low, ~12% below high. ATR 7.81 implies daily swing capacity.

True Sentiment Analysis (Delta 40-60 Options)

From ALNY_options_20261023_1513.json:

Call Volume: 96,500.00 (82.00%) Put Volume: 21,190.00 (18.00%) Total: 117,690.00

Sentiment tag: Bullish. Delta 40-60 filtered options show 32 call contracts vs 11 put contracts, 6 call trades vs 2 put trades. Pure directional conviction favors calls 4.6:1 by contracts. Near-term expectations lean bullish despite technical bearish stack. Divergence: option_spreads JSON notes "Options sentiment is Bullish but technicals are Bearish" and advises waiting for alignment.

Key Price Levels (Observational Only)